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Abstract 
Introduction: papillary thyroid microcarcinoma is a well-known malignant neoplasm with good prognosis. The known prognostic fac-
tors are patient’s age, multifocality, and extrathyroidal extension. CD9 and CD82, members of the tetraspanin family, are expressed in 
numerous cancer cells and play many roles associated with the cellular process. 
Material and methods: we investigated the immunohistochemical expression of CD9 and CD82 in papillary thyroid microcarcinoma and 
analysed the clinicopathological and prognostic significance. For the retrospective analysis, we collected the cases of 553 PTMC patients 
who had undergone thyroidectomy. 
Results: The group with lymph node metastasis showed higher immunostaining intensity for CD9 than the group without metastasis 
(p = 0.002). In multivariate analysis, high CD9 intensity (OR = 1.58 in 3+, p = 0.0025) correlated with lymph node metastasis. 
Conclusion: We suggest CD9 as a predictive prognostic factor for lymph node metastasis in PTMC. (Endokrynol Pol 2019; 70 (3): 224–231)
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Introduction
Papillary thyroid microcarcinoma (PTMC) is a well-known 
malignant neoplasm with good prognosis [1]. PTMC is 
defined as a papillary thyroid carcinoma with a tumour 
size less than 10 mm. Development of fine-needle aspira-
tion biopsy (FNAB) led to increased detection of newly 
diagnosed PTMC cases [2]. Because of the favourable 
prognosis and indolent biological behaviour, manage-
ment of PTMC has been controversial. Clinicians have 
a variety of options, from active surveillance to total 
thyroidectomy with lymph node dissection. Whichever 
treatment method is chosen, it is important to predict 
the prognosis of cancer patients for additional therapy 
or follow-up. In PTMC, the known prognostic factors 
associated with lymph node metastasis or tumour recur-
rence are patient’s age, multifocality, and extrathyroidal 
extension [3]. 
Several molecular prognostic factors of PTMC have 
been reported. BRAF mutation, which is commonly 
detected in papillary thyroid carcinoma, is associated 
with poor prognosis [4]. Another study reported that 
the absence of EGFR expression and COX-2 expression 
was associated with poor prognosis in patients with 
PTMC [5]. In addition, molecular studies of papillary 
carcinoma have been well studied, but rarely in mi-
crocarcinoma. 
CD9 and CD82, members of the tetraspanin family, 
are expressed in numerous cancer cells and mediate 
multiple cellular processes. Decreased CD9 expression 
has been reported to be related with the progression 
of breast, stomach, colon, prostate, and non-small cell 
lung cancer [6]. CD82 expression also has been reported 
to be related with the progression, metastasis, or poor 
prognosis of prostate, breast, larynx, gastrointestinal, 
and thyroid cancer [7–10]. However, the role of these 
molecules in PTMC is not well-known. 
In our previous study, CD82 expression is associated 
with poor prognosis of clear cell renal cell carcinoma 
(CCRCC) [11]. CCRCC shares some of the molecular 
changes with PTMC. The tumour suppressor gene, thy-
roid hormone receptor beta (THRB), is downregulated 
in other tumours including papillary thyroid carcinoma 
and has been reported to be downregulated in CCRCC 
[12, 13]. Therefore, some molecules may predict prog-
nosis in both PTMC and CCRCC. 
This study was designed to evaluate the immuno-
histochemical expression of CD9 and CD82 in PTMC 
and to determine the clinicopathological and prognostic 
significance.
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and CD82 expression and clinicopathological characteristics were 
analysed by Pearson’s c2 test. The H-score of CD9 and CD82 was 
also analysed by Pearson’s c2 test. The parameters that were sig-
nificant in the univariate analysis (p < 0.05) were analysed using 
a multivariate Cox regression model to evaluate the incremental 
statistical power and independence of prognostic impact. All of the 
statistical tests were two sided, and p values less than 0.05 were 
considered statistically significant.
Results
CD9 and CD82 expression in PTMC
CD9 was present in the cytoplasm and/or membrane, 
and of the 544 PTMC samples, 433 (80.6 %) were 
positive and 111 (20.4 %) were negative for CD9 im-
munohistochemical stain. CD82 was also observed in 
the cytoplasm and/or membrane. 375 (68.68%) were 
positive and 171 (31.32 %) were negative for CD82 im-
munohistochemical stain (Tab. II).
Association between CD9, CD82 expression, 
and clinicopathologic parameters
There was a statistically significant correlation between 
high CD9 immunostaining intensity and males com-
paring to females (p = 0.0089 and Pearson’s r = 0.001). 
In addition, the group with lymph node metastasis 
showed higher immunostaining intensity for CD9 than 
the group without metastasis (p = 0.002). The intensity 
of CD9 was found to be associated with N-stage. This 
was statistically significant (p = 0.0535). The higher 
CD82 immunostaining intensity was found to be as-
sociated with age (≤ 45) (p = 0.0226) and the absence of 
lymphocytic thyroiditis (p = 0.0111). Other parameters 
Material and methods
Patients and tissue specimens
For the retrospective analysis, we collected the cases of 553 PTMC 
patients who had undergone thyroidectomy from January to 
December 2010 at the Severance Hospital (Seoul, South Korea). 
Samples were obtained from 107 men and 446 women, with 
a mean age of 44.57 years. The mean tumour size was 0.53 cm. 
The clinicopathological information was collected from electronic 
medical records, pathological reports, and review of slides. The 
histologic subtype, tumour stage, and lymph node metastasis were 
determined by pathological review. The BRAF mutation was deter-
mined by polymerase chain reaction based on aspiration cytology 
or formalin-fixed, paraffin-embedded samples.
Tissue microarray and immunohistochemistry
The H&E slides of all cases were reviewed, and one representative 
core tissue (2mm in diameter) was obtained from each paraffin 
block and placed in a new paraffin block using a trephine apparatus 
(Superbiochips Laboratories, Seoul, Korea). Immunohistochemical 
staining was performed using the Bond-Max Autostainer (Leica 
Microsystems, IL, USA). After heat-induced antigen retrieval, mouse 
monoclonal anti-human CD9 antibody (NovoCastra, Newcastle 
Upon Tyne, UK, dilution 1:250) and mouse monoclonal anti-human 
CD82 antibody (NovoCastra, dilution 1:50) were incubated with 
the samples for 15 min. The binding of the primary antibody was 
detected using the Bond Polymer Refine Detection kit (Leica Mi-
crosystems) according to the manufacturer’s instructions. The CD9 
and CD82 immunoreactivity was scored using the H-score method, 
which classifies the percentages of cells stained with intensities of 
0, 1+, 2+, and 3+ as follows: H-score = S [Intensity (0, 1, 2, 3) × the 
extent of each staining intensity (%)] (Fig. 1). The H-score ranges from 0 
to 300. The results were evaluated independently by two pathologists 
who were blinded to the outcome and scores of the other observer.
Statistical analysis
Statistical analyses were performed using SPSS software (version 
23.0; SPSS Inc., Chicago, IL, USA). The correlations between CD9 
Figure 1. Each immunostained slide was classified into 0, 1+, 2+, or 3+ depending on the intensity of the staining. A. No expression (0); 
B. Weak intensity (1+); C. Moderate intensity (2+); D. Strong intensity (3+)
A B
C D
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did not show a significant correlation with the intensity 
of staining for CD9 and CD82 (Tab. III).
Association between H-score of CD9, CD82  
expression, and clinicopathological parameters
The CD9 H-score was significantly higher in the group 
with a size of less than 0.5 cm (p = 0.0240). Male gender 
(p = 0.0052) and presence of adenomatous hyperpla-
sia (p = 0.0272) also showed significantly high CD9 
H-score. The CD82 H-score did not show significant 
association with any clinicopathological parameters 
(Tab. IV).
Univariate and multivariate logistic regression 
for lymph node metastasis
In univariate analysis, age (≤ 45) (OR = 1.72, p = 0.0079), 
size (> 0.5 cm) (OR = 2.2, p < 0.0001), male gender 
(OR = 2.6, p < 0.0001), absence of lymphocytic thy-
roiditis (OR = 1.68, p = 0.021), and high CD9 intensity 
(OR = 1.95 in 3+, p = 0.0025) were correlated with 
lymph node metastasis. In multivariate analysis, age 
(≤ 45) (OR = 1.77, p = 0.0087), size (> 0.5 cm) (OR = 2.29, 
p = 0.0001), male gender (OR = 2.36, p = 0.0008), and 
high CD9 intensity (OR = 1.58 in 3+, p = 0.0061) were 
correlated with lymph node metastasis (Tab. V).
Discussion
Tetraspanin family molecules are involved in a variety 
of physiological and pathological processes including 
signal transduction, cell adhesion, proliferation, differ-
entiation, and migration [14, 15]. Among the tetraspanin 
family molecules, CD9 is one of the most studied mol-
ecules in human cancer, and there are many reports on 
its association with prognosis. A recent study reported 
that high expression of CD9 in colorectal cancer cells 
is associated with favourable disease-free survival [16]. 
In addition, follicular lymphoma, breast cancer, ovarian 
cancer, stomach, and malignant melanoma have been 
reported to show an inverse correlation between CD9 
expression and patient survival rate [17–21]. In this 
study, the association between CD9 expression and sur-
vival rate was not analysed, because most patients with 
PTMC are alive and the analysis may be insignificant. 
CD9 is also known as motility-related protein-1 
(MRP-1); one of the functions of CD9 in cancer cells is 
to contribute to cell motility and migration. Some stud-
ies suggested that CD9 is associated with EW1 family, 
epidermal growth factor receptor (EGFR), and discoidin 
domain receptor 1 (DDR1), regulating cell motility. The 
association with EGFR induces the EGF-dependent che-
motactic migration to extracellular matrix, and tumour 
cells gain the ability of extra- or intravasation [22–25]. 
Angiogenic activity of CD9 by interacting with vascular 
endothelial growth factor (VEGF) receptor 3 and integ-
rin has also been suggested [26, 27]. Our results showed 
Table I. Clinicopathological characteristics of the patients 
with papillary thyroid microcarcinoma (PTMC)
Characteristic Total (n = 553)
Age (years) ≤ 45 297 (53.71%)
> 45 256 (46.29%)
Size [cm] ≤ 0.5 325 (58.77%)
> 0.5 228 (41.23%)
Gender Male 107 (19.35%)
Female 446 (80.65%)
Location Left 271 (49.01%)
Right 282 (50.99%)
Tumour extent Intrathyroidal 336 (60.76%)
Extrathyroidal 217 (39.24%)
LN metastasis Absent 368 (72.44%)
Present 140 (27.56%)
N-stage N0 367 (66.37%)
N1a 127 (22.97%)
N1b 14 (2.53%)
Nx 45 (8.14%)
BRAF mutation Negative 17 (3.07%)
Positive 37 (6.69%)
Not performed 499 (90.24%)
Adenomatous hyperplasia Absent 440 (79.57%)
Present 113 (20.43%)
Lymphocytic thyroiditis Absent 387 (69.98%)
Present 166 (30.02%)
Table II. CD9 and CD82 expression in papillary thyroid 
microcarcinoma (PTMC)
Total (n = 533)
CD9
Expression (%)
0 111 (20.4%)
> 0 433 (80.6%)
Intensity
0 111 (20.4%)
1 200 (36.76%)
2 191 (35.76%)
3 42 (7.72%)
H-score (mean ± SD) 100.09 ± 87.10
CD82
Expression (%)
0 171 (31.32%)
> 0 375 (68.68%)
Intensity
0 171 (31.32%)
1 213 (39.01%)
2 124 (22.71%)
3 37 (6.78%)
H-score (mean ± SD) 93.42 ± 90.71
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that CD9 staining intensity was positively correlated 
with lymph node metastasis. This result appears to be 
due to the mechanisms described above.  
Paradoxically, several reports suggested that CD9 in-
hibits metastasis. In cancer cell line studies, a suggested 
mechanism is inhibition of integrin-mediated motility 
of various cancer cells including lung, breast, stomach, 
skin, pancreas, and urinary bladder [28]. Other studies 
suggested that CD9 may downregulate Wiskott-Aldrich 
syndrome protein 2 (WAVE 2), and downregulated 
WAVE 2 results in suppression of tumour cell motility 
by affecting the actin cytoskeleton [29, 30]. 
There are also some studies about other mecha-
nisms that CD9 is involved in in various cancer 
cells. One study reported that downregulation of CD9 
in pancreatic cancer cells induces upregulation of the 
epidermal growth factor, thereby promoting cancer cell 
growth and metastasis [31]. In ovarian cancer, upregu-
lation of CD9 is related to the induction of TNF-a gene 
expression and constitutive NF-kB activation [32]. In 
a review article, the function of CD9 is summarised 
as follows: i) interaction with endothelial cells and 
induction of transendothelial migration of the tumour 
cells; ii) enhancement of the motility of tumour cells; 
iii) promotion of tumour cell growth and prevention 
of apoptosis; and iv) an important marker for the 
identification of cancer stem cells [33]. These various 
mechanisms suggest that CD9 may affect prognosis in 
a variety of ways.
CD82 (KAI1) also belongs to the tetraspanin fam-
ily, and there have been studies about functions in 
cancer cells. Recent studies have suggested that CD82 
expression suppresses environmental angiogenesis 
by inhibition of production of interleukin 6 (IL-6) and 
vascular endothelial growth factor (VEGF) in malignant 
melanoma [34].  In the papillary thyroid carcinoma, 
down-regulation of CD82 is significantly related to 
lymph node metastasis and anaplastic transformation 
[35]. Another study reported that CD82 expression was 
correlated with pathological TNM status of thyroid 
cancer, and they suggested that down-regulation of 
CD82 expression in thyroid cancer cells may reflect 
an increased metastatic potential [10]. In this study, 
however, CD82 expression is correlated with patient 
age and lymphocytic thyroiditis, not with lymph node 
metastasis. Contrary to the above studies, normal an-
giogenesis without obvious vascular defect was shown 
in CD82-null mice [36]. The role of CD82 in cancer cells 
remains unclear.
H-score of CD9 is associated with adenomatous 
hyperplasia alone, and that of CD82 is not correlated 
with any clinicopathological parameters. Because the H-
score is the value obtained by multiplying the staining 
intensity by the extent, the staining extent seems not to Ta
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be important in affecting clinicopathological parameters 
in both CD9 and CD82 immunostaining.
This study represents an analysis of the association 
between two tetraspanin family molecules and clini-
copathologic parameters of PTMC, especially lymph 
node metastasis. Although CD9 staining intensity is 
significantly associated with lymph node metastasis, 
it is difficult to predict the complicated mechanism of 
lymph node metastasis based only on CD9 and CD82. 
Additional risk factors may affect CD9 expression and 
lymph node metastasis. The detailed mechanism should 
be elucidated through additional studies using various 
molecules and cancer cell lines.
Conclusion
In conclusion, although PTMC has a favourable progno-
sis, predicting the prognostic factors is very important 
for patient management. We suggest CD9 as a predic-
tive prognostic factor for lymph node metastasis in 
PTMC. Further studies with other cancers are needed 
to delineate the function of CD9. 
Table IV. Univariate and multivariate logistic regression for lymph node metastasis
CD9 CD82
H-score p-value H-score p-value
Age (years) 0.0006 0.8822 0.074 0.086
≤ 45 101.1 ± 86.60 0.7650 88.29 ± 92.40 0.1568
> 45 98.89 ± 87.82 99.31 ± 88.53
Size 0.097 0.0240 0.057 0.1857
≤ 0.5 97.33 ± 87.15 0.3803 89.47 ± 90.43 0.2266
> 0.5 104.0 ± 87.06 99.0 ± 91.0
Gender
Male 121.1 ± 89.19 0.0052 98.97 ± 90.87 0.4803
Female 94.94 ± 85.90 92.06 ± 90.72
Location 
Left 99.37 ± 87.07 0.8482 91.83 ± 89.07 0.6799
Right 100.8 ± 87.27 95.04 ± 92.48
Tumour extent
Intrathyroidal 102.3 ± 88.42 0.4596 96.51 ± 95.30 0.3091
Extrathyroidal 96.66 ± 85.10 88.65 ± 83.13
LN metastasis
Absent 96.26 ± 83.42 0.2043 89.67 ± 86.72 0.0533
Present 11.4 ± 94.90 93.81 ± 95.78
N-stage
N0 96.25 ± 83.42 0.2043 89.67 ± 86.72 0.0533
N1a 108.32 ± 95.89 97.82 ± 97.25
N1b 138.21 ± 79.65 58.21 ± 70.15
Nx 96.14 ± 91.05 122.84 ± 103.41
BRAF mutation
Negative 93.53 ± 93.45 0.6509 92.94 ± 119.8 0.4627
Positive 105.1 ± 84.01 116.2 ± 101.3
Adenomatous hyperplasia
Absent 95.94 ± 85.47 0.0272 94.53 ± 91.26 0.5708
Present 116.5 ± 91.80 89.05 ± 88.79
Lymphocytic thyroiditis
Absent 101.9 ± 87.86 0.4589 97.44 ± 94.98 0.0878
Present 95.86 ± 85.39 83.96 ± 79.24
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Table V. Univariate and multivariate logistic regression for lymph node metastasis
Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Age (years)
≤ 45 1.72 (1.15~2.58) 0.0079 1.77 (1.16~2.72) 0.0087
> 45 1 1
Size
≤ 0.5 1 < 0.0001 1 0.0001
> 0.5 2.2 (1.48~3.26) 2.29 (1.51~3.48)
Gender
Male 2.6 (1.64~4.15) < 0.0001 2.36 (1.43~3.90) 0.0008
Female 1 1
Location 
Left 1 0.6661
Right 1.09 (0.74~1.61)
Tumour extent
Intrathyroidal 1 0.7443
Extrathyroidal 1.07 (0.72~1.59)
BRAF mutation
Negative 0.13 (0.02~1.12) 0.0635
Positive 1
Adenomatous hyperplasia
Absent 1 0.4329
Present 0.82 (0.50~1.34)
Lymphocytic thyroiditis
Absent 1.68 (1.08~2.62) 0.021 1.41 (0.88~2.26) 0.154
Present 1 1
CD9 Expression
 1 1 0.9644
 2 1.23 (0.53~2.83)
 3 1.00 (0.48~2.10)
 4 1.01 (0.61~1.67)
CD9 Intensity
 0 1 0.0025 1 0.0061
 1 0.62 (0.35~1.09) 0.51 (0.28~0.93)
 2 1.37 (0.81~2.34) 1.1 (0.63~0.1.92)
 3 1.95 (0.90~4.24) 1.58 (0.69~3.58)
CD9 H-score 1.00 (0.99~1.004) 0.0817
CD82 Expression
 1 1 0.8485
 2 1.06 (0.44~1.68)
 3 1.60 (0.55~4.65)
 4 1.00 (0.65~1.53)
CD82 Intensity
 0 1 0.0803
 1 1.06 (0.67~1.68)
 2 0.77 (0.44~1.35)
 3 2.35 (1.06~5.21)
CD82 H-score 1.001 (0.99~1.003) 0.6432
OR — odds ratio; CI — confidence interval
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